Skip to search formSkip to main contentSkip to account menu

XL647

National Institutes of Health

Related topics

Related topics

6 relations

Broader (4)

Azabicyclo CompoundsPharmacologic SubstanceQuinazolinesTesevatinib
EXEL-7647KD019

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2008
Review
2008
ASCO presentations highlight value of cancer biomarkers
Nature Reviews Drug Discovery 7, 547–549 (July 2008) | doi:10.1038/nrd2633 This article stated that: “Clinicians are looking at… 
2007
2007
A phase I dose-escalation and pharmacokinetic (PK) study of XL647, a novel spectrum selective kinase inhibitor, administered orally daily to patients with advanced solid malignancies (ASM)
B242 Background: XL647 is an orally bioavailable small molecule inhibitor of multiple receptor tyrosine kinases involved in… 
2006
2006
342 POSTER A phase I dose-escalation and pharmacokinetic (PK) study of XL647, a novel spectrum selective kinase inhibitor, administered orally to patients with advanced solid malignancies (ASM)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)